Jesduvroq (daprodustat) for anemia of chronic kidney disease in dialysis patients
Cigna coverage policy for prior authorization and medical necessity criteria for Jesduvroq (daprodustat) for treatment of anemia due to chronic kidney disease in adults receiving dialysis; includes initial and continuation criteria, employer-plan step requirements, and conditions considered not medically necessary.
New policy created (New Policy dated 03/15/2024).
Language changed from 'Individual' to 'Patient' throughout the policy.
Continuation therapy criterion updated from requiring demonstration of a 'beneficial response' defined by enumerated items to 'According to the prescriber, patient has experienced a response to therapy' with examples moved to a note.
Employer plan preferred product criteria updated from requiring 'documentation of failure, contraindication, or intolerance' to 'patient has tried, and according to the prescriber, has experienced inadequate efficacy OR significant intolerance with ONE of the following' epoetin/Aranesp/Mircera.
Condition 'Concurrent Use with Vafseo (vadadustat tablets)' added to Conditions Not Covered.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.